StockNews.AI
AXGN
StockNews.AI
4 hrs

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

1. Pomerantz LLP investigates potential securities fraud by Axogen's leadership. 2. Axogen's FDA application review delayed by three months, impacting stock value. 3. Stock price fell 9.04% following the FDA announcement on August 25, 2025. 4. Investors can join a class action against Axogen over these claims. 5. Pomerantz LLP has a strong track record in securities class actions.

4m saved
Insight
Article

FAQ

Why Bearish?

The investigation implies potential legal troubles and lowers investor confidence. Historical precedents show that similar investigations often lead to declining stock prices.

How important is it?

Legal investigations can profoundly impact stock evaluations and investor trust. Prompt investor reactions in the face of legal scrutiny can drastically shake stock prices.

Why Short Term?

The immediate legal investigation could trigger additional selling pressure. Past cases demonstrate quick responses from investors in similar situations.

Related Companies

AKRXNERVAXGN
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Axogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 25, 2025, Axogen issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025."  On this news, Axogen's stock price fell $1.47 per share, or 9.04%, to close at $14.79 per share on August 25, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980  SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News